Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) [Phase 1]

View source ↗

Summary

Phase 1 trial MK-2870-008 evaluating sacituzumab govitecan as a single agent and in combination with pembrolizumab for advanced solid tumors, including non-smal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer, Solid Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING